

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

**GORDON MILLS et al.**

Serial No.: Not Yet Assigned

Filed: Herewith

For: **METHOD FOR DETECTING  
CANCER ASSOCIATED WITH  
ELEVATED LEVELS OF  
LYSOPHOSPHOLIPIDS**

)  
) Previous Group Art Unit No. 1642

)  
) Previous Examiner: Karen A. Canella

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

IN THE SPECIFICATION:

On page 1 of the specification before "Introduction" please insert the following:

Related Information

This application is a continuation of U.S. Patent Application Serial No. 08/822,128 filed on March 21, 1997. The priority of the prior applications are expressly claimed, and the disclosure of each of these prior applications is hereby incorporated by reference in its entirety.

CERTIFICATE OF MAILING  
(37 C.F.R. §1.10)


I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

EV 051628979 US  
Express Mail Label No.

February 26, 2002  
Date of Deposit

Lynne Fulmer

Name of Person Mailing Paper

  
Signature of Person Mailing PaperOC-104708.1

IN THE CLAIMS:

Please cancel claims 1-47 without prejudice and insert the following new claims.

48. A method to detect a gynecological cancer comprising:

(a) determining the concentration of LysoPA and LysoPI in a sample of bodily fluid

taken from a patient;

(b) comparing the concentration of LysoPA and LysoPI to normal concentrations;

(c) and correlating an altered concentration of LysoPA and LysoPI to the presence of cancer.

49. The method of claim 48 further comprising the step of determining the concentration of a subtype of LysoPA in the sample.

50. The method of claim 48 further comprising the step of determining the concentration of a subtype of LysoPI in the sample.

51. The method of claim 48 wherein said method comprises the step of measuring a subtype concentration of palmitoyl-X, stearoyl-X, oleoyl-X or linoleoyl-X in the sample from the patient, where X is LysoPA or LysoPI and comparing the subtype concentration to a control concentration.

52. The method of claim 40 wherein the subtype concentration is palmitoyl-LysoPI.

53. The method of claim 50 wherein the subtype concentration is linoleoyl-LysoPI.

54. The method of claim 50 wherein the subtype concentration is oleoyl-LysoPA.

55. The method of claim 48 further comprising the step of determining the concentration of an additional cancer marker.

56. The method of claim 55 wherein said marker is selected from the group consisting of CA125, Tac, soluble IL2 receptor alpha, mCSF, OVX1, CEA, PSA, CA15-3 and CA19.9.

57. The method of claim 48 wherein the concentration of LysoPA and LysoPI is determined at successive time intervals to measure a change over time for the concentration of LPA and LPI in the bodily fluid from the patient.

58. The method of claims 48, 49, 50, 51, 52, 53, 54, 55, 56 or 57 wherein the sample of bodily fluid is plasma.


59. The method of claims 48, 49, 50, 51, 52, 53, 54, 55, 56 or 57 wherein the sample of bodily fluid is serum.

Respectfully submitted,

LYON & LYON LLP

Dated: February 26, 2002

By:

  
Kurt T. Mulville  
Reg. No. 37,194  
Attorneys for Applicant

633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066  
949/567-2300 X 1124  
213/955-0440 Facsimile